Zymeworks Inc. (ZYME) Form 8-K — Oct 23, 2026
$ZYMEForm 8-KItems 1.01, 7.01, 9.01Filed Oct 23, 2026, 6:07 AM ET0001937653-26-000055Original filing
Zymeworks entered an exclusive global license and collaboration agreement with Roche for ZW209, its trispecific T-cell engager targeting DLL3-expressing tumors. Roche gains worldwide rights to develop and commercialize ZW209. Zymeworks will receive a $55 million upfront payment plus a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional development, commercial and sales-based milestones. Royalties are tiered high-single-digit to mid-teen on global net sales.
Key figures
- Royalty Rate
- tiered high-single-digit to mid-teen royalties on annual net sales
- Hsr Clearance
- required before license effective date
- Upfront Payment
- 55000000
- Milestone Payments
- {"phase1bInitiation":40000000,"developmentCommercialSales":718000000}
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.